Ann Thorac Med 2017 Oct-Dec;12(4):294-297
Department of Medical Specialties, Rheumatology Section, King Fahad Medical City, Riyadh, KSA.
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Arthritis Rheumatol 2015 Dec;67(12):3256-61
University Hospital Zurich, Zurich, Switzerland.
Objective: Validated methods for the screening and early diagnosis of systemic sclerosis (SSc; scleroderma)-related interstitial lung disease (ILD) are needed. The aim of this study was to evaluate the performance of pulmonary function tests (PFTs) compared with that of high-resolution computed tomography (HRCT) of the chest for the detection of SSc-related ILD in clinical practice, and to identify predictors of lung involvement that is functionally occult but significant on HRCT.
Methods: Prospectively enrolled patients with SSc were assessed according to the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research standards. Read More
Rheumatology (Oxford) 2015 Aug 3;54(8):1420-8. Epub 2015 Mar 3.
Institute of Clinical Medicine, Department of Rheumatology.
Objective: To retrospectively evaluate the efficacy and safety of rituximab (Rtx) treatment in patients with anti-synthetase syndrome (ASS) and severe interstitial lung disease (ILD).
Methods: Patients with severe ILD and >12 months follow-up post-Rtx were identified from the Oslo University Hospital ASS cohort (n = 112). Clinical data, including pulmonary function tests (PFTs), were retrospectively collected from medical reports. Read More
Autoimmun Rev 2011 Mar 21;10(5):248-55. Epub 2010 Sep 21.
Université Paris Descartes, Institut Cochin, Inserm U1016, Paris, France.
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies. ILD develops in up to 75% of patients with SSc overall. However, SSc-ILD evolves to end-stage respiratory insufficiency in only a few patients. Read More
Rheumatology (Oxford) 2010 Feb 15;49(2):271-80. Epub 2009 May 15.
Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, 26504 Rion, Patras, Greece.
Objective: To assess the efficacy of rituximab (RTX) in SSc.
Methods: Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, whereas six patients (control group) received standard treatment alone. Read More